Controlled proteolytic cleavage site presentation in biomimetic PEGDA hydrogels enhances neovascularization in vitro.
The volume of tissue that can be engineered is limited by the extent to which vascularization can be stimulated within the scaffold. The ability of a scaffold to induce vascularization is highly dependent on its rate of degradation. We present a novel approach for engineering poly (ethylene glycol) diacrylate (PEGDA) hydrogels with controlled protease-mediated degradation independent of alterations in hydrogel mechanical and physical properties. Matrix metalloproteinase (MMP)-sensitive peptides containing one (SSite) or three (TriSite) proteolytic cleavage sites were engineered and conjugated to PEGDA macromers followed by photopolymerization to form PEGDA hydrogels with tethered cell adhesion ligands of YRGDS and with either single or multiple MMP-sensitive peptide domains between cross links. These hydrogels were investigated as provisional matrices for inducing neovascularization, while maintaining the structural integrity of the hydrogel network. We show that hydrogels made from SSite and TriSite peptide-containing PEGDA macromers polymerized under the same conditions do not result in alterations in hydrogel swelling, mesh size, or compressive modulus, but result in statistically different hydrogel degradation times with TriSite gels degrading in 1-3 h compared to 2-4 days in SSite gels. In both polymer types, increases in the PEGDA concentration result in decreases in hydrogel swelling and mesh size, and increases in the compressive modulus and degradation time. Furthermore, TriSite gels support vessel invasion over a 0.3-3.6 kPa range of compressive modulus, while SSite gels do not support invasion in hydrogels above compressive modulus values of 0.4 kPa. In vitro data demonstrate that TriSite gels result in enhanced vessel invasion areas by sevenfold and depth of invasion by twofold compared to SSite gels by 3 weeks. This approach allows for controlled, localized, and cell-mediated matrix remodeling and can be tailored to tissues that may require more rapid regeneration and neovascularization.
Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, USA.
Sonja
S
Sokic
Georgia
G
Papavasiliou
D040761:Biomimetic Materials / Q000494:pharmacology*; D018920:Coculture Techniques; D017364:Collagenases / Q000494:pharmacology; D019245:Compressive Strength; D003432:Cross-Linking Reagents / Q000494:pharmacology; D061307:Human Umbilical Vein Endothelial Cells / Q000166:cytology; D006801:Humans; D020100:Hydrogels; D020782:Matrix Metalloproteinases / Q000378:metabolism; D032389:Myocytes, Smooth Muscle / Q000166:cytology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010446:Peptide Fragments / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D016062:Porosity; D059748:Proteolysis; D018874:Spheroids, Cellular; D013268:Stimulation, Chemical; D054457:Tissue Scaffolds; D014469:Umbilical Arteries / Q000166:cytology
D003432:Cross-Linking Reagents; D020100:Hydrogels; D010446:Peptide Fragments; C437167:poly(ethylene glycol)diacrylate; D011092:Polyethylene Glycols; D017364:Collagenases; D020782:Matrix Metalloproteinases